复方苦参注射液对非小细胞肺癌血清中CA125、CEA、VEGF表达的影响

Effect of compound matrine injection on the expression of CEA, VEGF and CA125 in non small cell lung cancer patients

目的探讨复方苦参注射液对非小细胞肺癌血清中血清糖类抗原（CA125）、癌胚抗原（CEA）、血管内皮生长因子（VEGF）表达的影响。方法70例非小细胞肺癌患者按照就诊顺序分为实验组和对照组各35例。患者给予常规西药治疗，实验组患者在对照组的基础上给予复方苦参注射液，治疗结束后，对所有患者血清中CA125、VEGF、基质金属蛋白酶9（MMP-9）以及金属蛋白酶组织抑制剂（TIMP-1）水平情况进行检测。结果实验组与对照组相比，血清CA125、CEA、VEGF以及MMP-9水平较低（P〈0.05）；TIMP-1水平较高（P〈0.05）。结论复方苦参注射液能够显著降低非小细胞肺癌患者血清CA125、CEA、VEGF以及MMP-9水平，提高血清TIMP-1水平，抑制肿瘤细胞的侵袭、转移、扩散，具有临床指导意义。

Objective To investigate the effect of compound matrine injection on the expression of CEA, VEGF and CA125 in non small cell lung cancer patients.MethodsSeventy non small cell lung cancer patients were selected and divided into the control group and the experiment group according to the order of medical treatment. The control group were treated with conventional western medicine, and the experiment group, on the basis of the treatment in control group, were additionally treated with compound matrine injection. The levels of serum CA125, CEA, MMP-9, VEGF and TIMP-1 in all patients were tested and compared after treatment.ResultsCompared with the control group, the levels of CA125, CEA, MMP-9, VEGF after treatment were lower in experiment group （P〈0.05）; the TIMP-1 level were higher in experiment group （P〈0.05）.ConclusionsCompound matrine injection can significantly reduce the levels of serum CA125, VEGF, CEA and MMP-9 in patients with non small cell lung cancer, improve the level of serum TIMP-1, and inhibit tumor cell invasion, metastasis and proliferation, which has significance for clinical guidance.